Advances in the treatment of juvenile myelomonocytic leukemia.
- Author:
Yu-Li CAI
1
;
Jing-Liao ZHANG
;
Xiao-Fan ZHU
Author Information
1. Department of Pediatrics, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences, Tianjin 300020, China. lily4e09@163.com.
- Publication Type:Journal Article
- MeSH:
Child;
Hematopoietic Stem Cell Transplantation;
Humans;
Leukemia, Myelomonocytic, Juvenile;
Methylation;
Myelodysplastic Syndromes;
Signal Transduction
- From:
Chinese Journal of Contemporary Pediatrics
2018;20(11):958-963
- CountryChina
- Language:Chinese
-
Abstract:
Juvenile myelomonocytic leukemia (JMML) is a rare chronic myeloid leukemia in children and has the features of both myelodysplastic syndrome and myeloproliferative neoplasm. It is highly malignant and has a poor treatment outcome. Children with JMML have a poor response to conventional chemotherapy. At present, hematopoietic stem cell transplantation is the only possible cure for this disease. In recent years, significant progress has been made in targeted therapy for mutant genes in the Ras signaling pathway and demethylation treatment of aberrant methylation of polygenic CpG islands. This article reviews the treatment and efficacy evaluation of JMML.
